Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by retiredcopon Jul 24, 2021 1:20pm
152 Views
Post# 33600988

Lack to reliable testing

Lack to reliable testing

Reader bemoans lack of precise post-vaccine immunity testing

By Keith Roach, M.D. on 

DEAR DR. ROACH: Can you comment on the lack of a test that truly demonstrates the effective level of immunity an individual has from receiving the COVID vaccine? My wife has lupus and rheumatoid arthritis, and had both doses of the Pfizer vaccine over a month ago. Now we learn that her immune system may not have created any antibodies against COVID-19! There is no test to give her peace of mind that she is protected. The one test mentioned (SARS-CoV-2 Semi-Quantitative Total Antibody, Spike) shows only that you have some antibodies from the vaccine, but doesn't reveal the true level of protection. It's frustrating! -- B.W.

ANSWER: I completely agree that the lack of a blood test that can reliably identify people who are at risk for developing COVID-19 -- or alternatively, those who have reliable protection -- is extremely frustrating. For many vaccines, we do have such a test for effectiveness. For measles or rubella, for example, a person can get the blood test, and if the antibody isn't present at a high-enough level, we know they are at risk and recommend booster shots. Unfortunately, we do not have that test for COVID-19 at the time of this writing.

There are many different kinds of antibody tests a physician can order, but it is unknown whether the absence of antibodies indicates a person is at risk, nor whether their presence is reliable proof of immunity. The Centers for Disease Control and Prevention notes: "none of the currently authorized tests have been authorized to assess individuals that have received a vaccine" and "antibody testing is not currently recommended to assess for immunity to COVID-19 following COVID-19 vaccination or to assess the need for vaccination in an unvaccinated person." I sincerely hope that by the time this column is published or shortly thereafter, we will have a reliable test. This would be very useful, especially for people such as your wife, who are at higher risk for complications of COVID-19 and who have a reduced response to the vaccine due to medications she might be taking for her lupus and rheumatoid arthritis.

<< Previous
Bullboard Posts
Next >>